Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,159 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fluarix Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

NCT01416571
View directory record Official record
Conditions
Influenza
Interventions
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 20, 2026, 7:17 AM EDT
Withdrawn No phase listed Observational

Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy

NCT01146353
View directory record Official record
Conditions
Influenza, Renal Failure
Interventions
Not listed
Lead sponsor
Midwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 20, 2026, 7:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of a Flu Vaccine in Children

NCT00001127
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (CAIV-T)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Months to 18 Years
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 20, 2026, 7:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations

NCT00943631
View directory record Official record
Conditions
Influenza
Interventions
Inactivated H1N1 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
Baltimore, Maryland • Durham, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 20, 2026, 7:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Beta-glucan and Immune Response to Influenza Vaccine

NCT05074303
View directory record Official record
Conditions
Healthy Aging
Interventions
Influenza Vaccine, Beta-glucan, Placebo
Biological · Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
50 Years to 100 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 20, 2026, 7:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fever After Simultaneous Versus Sequential Vaccination in Young Children

NCT03165981
View directory record Official record
Conditions
Fever After Vaccination, Fever, Febrile Seizure
Interventions
PCV13, DTaP, IIV
Biological
Lead sponsor
Duke University
Other
Eligibility
12 Months to 16 Months
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Oakland, California • Atlanta, Georgia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 20, 2026, 7:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4

NCT00538512
View directory record Official record
Conditions
Influenza
Interventions
Fluzone, Flumist, Physiologic saline
Biological · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 49 Years
Enrollment
1,952 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Ann Arbor, Michigan • Kalamazoo, Michigan • Mount Pleasant, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 20, 2026, 7:17 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A/H5N1 Vaccine in Healthy Children Aged 2-9 Years

NCT00133536
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H5N1 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 9 Years
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
4
States / cities
Torrance, California • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 20, 2026, 7:17 AM EDT
Completed Not applicable Interventional

Nudging Flu Vaccination in Patients at Moderately High Risk for Flu and Flu-related Complications

NCT05509283
View directory record Official record
Conditions
Influenza, Vaccination, Health Promotion, Health Behavior, Risk Reduction
Interventions
Risk Reduction
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
40,671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 20, 2026, 7:17 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines

NCT07493460
View directory record Official record
Conditions
Immunology, Healthy Adults
Interventions
trivalent inactivated influenza vaccine (TIV), nonavalent HPV vaccine (HPV), hepatitis A (HAV) vaccines, tetanus, diphtheria and acellular pertussis vaccine (Tdap)
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 20, 2026, 7:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

NCT03314662
View directory record Official record
Conditions
Influenza, Human
Interventions
MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV), Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1), MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
65 Years and older
Enrollment
1,778 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
20
States / cities
Mobile, Alabama • Anaheim, California • Redding, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 20, 2026, 7:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM

NCT01011049
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine USP Trivalent Types A and B
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
44
States / cities
Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 20, 2026, 7:17 AM EDT
Completed No phase listed Observational

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

NCT03056924
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 20, 2026, 7:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations

NCT01746082
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H3N2 variant Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
4
States / cities
Decatur, Georgia • Iowa City, Iowa • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2014 · Synced Oct 20, 2026, 7:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults

NCT04579250
View directory record Official record
Conditions
Influenza
Interventions
VRC-FLUNPF0103-00-VP (H10ssF-6473)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 20, 2026, 7:17 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)

NCT02500680
View directory record Official record
Conditions
Influenza, Human
Interventions
MER4101, Inactivated Influenza Vaccine
Biological
Lead sponsor
Nova Immunotherapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 20, 2026, 7:17 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus

NCT02950688
View directory record Official record
Conditions
Influenza, Human
Interventions
Seasonal LAIV, Placebo, Wild-type A/California/2009-like Influenza Virus
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Oct 20, 2026, 7:17 AM EDT
Completed No phase listed Observational

Influenza in People With Normal and Weakened Immune Systems

NCT00533182
View directory record Official record
Conditions
Viral Infections, Respiratory Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 20, 2026, 7:17 AM EDT
Completed Not applicable Interventional Results available

Text2Breathe: Enhance Parent Communication to Reduce Pediatric Asthma Disparities

NCT03032159
View directory record Official record
Conditions
Asthma
Interventions
Text2Breathe Study Group
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Seattle, Washington • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 20, 2026, 7:17 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Woodsmoke Exposure, Influenza Infection, and Nasal Immunity

NCT06841913
View directory record Official record
Conditions
Smoke Exposure, Influenza
Interventions
LAIV nasal vaccine is chosen as a model viral infection, Wood smoke, Placebo for LAIV nasal vaccine is chosen as a model viral infection, Placebo for Wood Smoke (clean Air Exposure)
Biological · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 20, 2026, 7:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Avian Influenza Studies In Lebanon

NCT01107262
View directory record Official record
Conditions
Avian Influenza, Virus Diseases
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 27, 2011 · Synced Oct 20, 2026, 7:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Immune Response to High-Dose vs. Standard Dose Influenza Vaccine

NCT02297542
View directory record Official record
Conditions
Elderly Immune System
Interventions
Flu Vaccine
Biological
Lead sponsor
Health Sciences North Research Institute
Other
Eligibility
20 Years and older
Enrollment
393 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 7:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza

NCT06179446
View directory record Official record
Conditions
Grippe, Influenza, Vaccines
Interventions
pdmFlu vaccine, Placebo, Licensed influenza vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 84 Years
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
New Haven, Connecticut • Hollywood, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 20, 2026, 7:17 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

NCT05650554
View directory record Official record
Conditions
Influenza Immunization
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5413, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
28
States / cities
Chula Vista, California • Gardena, California • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 20, 2026, 7:17 AM EDT